RARE · CIK 1515673
What Ultragenyx Pharmaceutical Inc. told the SEC could break it.
Ultragenyx's supply chain is thin: it acquires most of the drug substances and finished products behind its medicines from single sources (including KKC, Regeneron and IOI Oleo), so if one breaches, terminates, ceases operations or is acquired, it could face significant expense, supply disruption or delayed commercialization. Geography compounds that fragility — its headquarters and a lab sit in the earthquake-prone San Francisco Bay Area and its sole Crysvita supplier KKC is in Japan, both quake-prone regions, and it carries no earthquake insurance. Trade policy is a third, emerging threat: with its products made by contract manufacturers in Western Europe and Japan, it is exposed to U.S. pharmaceutical tariffs, including a September 2025 announcement of potential future tariffs of up to 100% on branded drugs imported into the U.S. unless the importer is building domestic capacity.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- single-source drug substance & product manufacturinghigh
Ultragenyx acquires most of its drug substances and drug products from single sources (KKC, Regeneron, IOI Oleo, etc.); loss of a single-source supplier could cause significant expense, supply disruption or delayed commercialization.
“We acquire most of the drug substances and drug products for our products and product candidates from single sources. If any single source supplier breaches an agreement with us, or terminates the agreement in response to an alleged breach by us, ceases operations, is acquired, enters into exclusive arrangements with a competitor or otherwise becomes unable or unwilling to fulfill its supply obligations,”
SEC filing →As of 2026
Climate & physical
- earthquake exposure (SF Bay Area / Japan), uninsuredmedium
Ultragenyx's headquarters and a lab are in the earthquake-prone San Francisco Bay Area, and its sole Crysvita supplier KKC is in Japan; the company carries no earthquake insurance, so a major quake could severely disrupt operations.
“Our corporate headquarters and one of our laboratories are located in the San Francisco Bay Area, and our collaboration partner for Crysvita, KKC, is located in Japan, which have both in the past experienced severe earthquakes and other natural disasters. We do not carry earthquake insurance.”
SEC filing →As of 2026
Regulatory & policy
- US pharmaceutical tariffsmedium
The U.S. administration has imposed tariffs on pharmaceutical products and in September 2025 announced potential future tariffs of up to 100% on branded/patented pharmaceuticals imported into the U.S. unless the company is building U.S. capacity — relevant since Ultragenyx's products are made by CMOs in Western Europe and Japan.
“In September 2025, the Administration announced that future tariffs of up to 100% could be implemented affecting branded or patented pharmaceutical products coming into the U.S., unless the importing company is building U.S.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Kyowa Kirin Co. (KKC)
“For the year ended December 31, 2025, 45% of our total revenues were generated by our collaboration partner KKC.”
Cited →
Its suppliers
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch